- Home
- CLB vs PRAX Comparison
CLB vs PRAX Comparison
Compare CLB & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- PRAX
- Stock Information
- Founded
- CLB 1936
- PRAX 2015
- Country
- CLB United States
- PRAX United States
- Employees
- CLB N/A
- PRAX N/A
- Industry
- CLB
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- PRAX Health Care
- Exchange
- CLB Nasdaq
- PRAX Nasdaq
- Market Cap
- CLB 717.9M
- PRAX 599.7M
- IPO Year
- CLB 1995
- PRAX 2020
- Fundamental
- Price
- CLB $11.38
- PRAX $43.33
- Analyst Decision
- CLB Hold
- PRAX Strong Buy
- Analyst Count
- CLB 4
- PRAX 11
- Target Price
- CLB $15.00
- PRAX $114.73
- AVG Volume (30 Days)
- CLB 448.1K
- PRAX 287.9K
- Earning Date
- CLB 07-23-2025
- PRAX 08-12-2025
- Dividend Yield
- CLB 0.35%
- PRAX N/A
- EPS Growth
- CLB N/A
- PRAX N/A
- EPS
- CLB 0.59
- PRAX N/A
- Revenue
- CLB $517,796,000.00
- PRAX $8,122,000.00
- Revenue This Year
- CLB N/A
- PRAX N/A
- Revenue Next Year
- CLB $2.92
- PRAX $6,358.50
- P/E Ratio
- CLB $19.28
- PRAX N/A
- Revenue Growth
- CLB 1.32
- PRAX 270.02
- 52 Week Low
- CLB $10.15
- PRAX $26.70
- 52 Week High
- CLB $25.13
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- CLB 44.46
- PRAX 56.73
- Support Level
- CLB $11.78
- PRAX $40.86
- Resistance Level
- CLB $13.05
- PRAX $44.99
- Average True Range (ATR)
- CLB 0.52
- PRAX 2.50
- MACD
- CLB 0.00
- PRAX -0.22
- Stochastic Oscillator
- CLB 23.86
- PRAX 43.40
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.